- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation stock price live, this page displays NASDAQ DVAX stock exchange data. View the DVAX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Dynavax Technologies Corporation real time stock price chart below.
What Is the Dynavax Technologies Corporation Stock Price Today?
The Dynavax Technologies Corporation stock price today is 10.500.
What Is the Stock Symbol for Dynavax Technologies Corporation?
The stock symbol for Dynavax Technologies Corporation is ""DVAX.""
What Stock Exchange Does Dynavax Technologies Corporation Trade On?
Dynavax Technologies Corporation is listed and trades on the NASDAQ stock exchange.
Is Dynavax Technologies Corporation a Good Stock to Buy?
Determining whether Dynavax Technologies Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DVAX quote. (ISIN: US2681582019)
What Is the Dynavax Technologies Corporation Stock Price Today?
The Dynavax Technologies Corporation stock price today is 10.500.
What Is the Stock Symbol for Dynavax Technologies Corporation?
The stock symbol for Dynavax Technologies Corporation is ""DVAX.""
What Stock Exchange Does Dynavax Technologies Corporation Trade On?
Dynavax Technologies Corporation is listed and trades on the NASDAQ stock exchange.
Is Dynavax Technologies Corporation a Good Stock to Buy?
Determining whether Dynavax Technologies Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DVAX quote. (ISIN: US2681582019)
Fair Value
An estimate of a Dynavax's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.480
10.975
52 wk Range
9.220
14.630
DVAX Scorecard
Full Analysis
Management has been aggressively buying back shares
Unusual trading volume
1/2
Fair Value
An estimate of a Dynavax's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.48010.975
52 wk Range
9.22014.630
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DVAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Dynavax's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
23.250
Upside
+121.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Dynavax Technologies Corporation Company Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Dynavax Technologies Corporation SWOT Analysis
Vaccine Vanguard | Dynavax leads hepatitis B market with HEPLISAV-B, boasting 43% market share and record sales growth, while expanding into new vaccine territories |
Financial Fortitude | Strong balance sheet with more cash than debt, $75M+ EBITDA guidance for 2025, and ongoing share buyback program signal financial health |
Pipeline Potential | Explore Dynavax's diversification strategy, including promising shingles, H5N1 flu, and Lyme disease vaccine candidates leveraging proprietary adjuvant technology |
Market Momentum | Analyst targets range from $11.10 to $31.00, with expectations of 60%+ market share by 2030 in a U.S. hepatitis B vaccine market projected to exceed $900M |
Dynavax Technologies Corporation Earnings Call Summary for Q2/2025
- Q2 2025 EPS of $0.14 beat forecasts by 40%; revenue of $95.44M exceeded expectations by 11.53%
- HEPLISAV B vaccine market share rose to 45%; full-year revenue guidance set at $315M-$325M
- Company completed $200M share repurchase program; stock dipped 1.16% in after-hours trading
- Adjusted EBITDA reached $37M, up from $20M in 2024; at least $75M expected for full year
- Market shift towards retail noted; strong relationship with DoD for plague vaccine program continues
Last Updated: 08/08/2025, 10:48
Read Full TranscriptCompare DVAX to Peers and Sector
Metrics to compare | DVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDVAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −23.4x | −3.0x | −0.6x | |
PEG Ratio | 0.05 | −0.07 | 0.00 | |
Price/Book | 2.5x | 1.2x | 2.6x | |
Price / LTM Sales | 3.9x | 7.9x | 3.3x | |
Upside (Analyst Target) | 136.1% | 23.3% | 40.0% | |
Fair Value Upside | Unlock | 14.8% | 4.7% | Unlock |
Analyst Ratings
4 Buy
0 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 23.250
(+121.43% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
0.14 / 0.10
Revenue / Forecast
95.44M / 85.57M
People Also Watch
FAQ
What Stock Exchange Does Dynavax Trade On?
Dynavax is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Dynavax?
The stock symbol for Dynavax is "DVAX."
What Is the Dynavax Market Cap?
As of today, Dynavax market cap is 1.23B.
What Is Dynavax's Earnings Per Share (TTM)?
The Dynavax EPS (TTM) is -0.42.
When Is the Next Dynavax Earnings Date?
Dynavax will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is DVAX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Dynavax Stock Split?
Dynavax has split 1 times.
How Many Employees Does Dynavax Have?
Dynavax has 405 employees.
What is the current trading status of Dynavax (DVAX)?
As of 22 Aug 2025, Dynavax (DVAX) is trading at a price of 10.50, with a previous close of 10.95. The stock has fluctuated within a day range of 10.48 to 10.98, while its 52-week range spans from 9.22 to 14.63.
What Is Dynavax (DVAX) Price Target According to Analysts?
The average 12-month price target for Dynavax is USD23.25, with a high estimate of USD32 and a low estimate of USD11. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +121.43% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.